Switch studies in virologically suppressed patients
Download the slides

Related articles :
Table of contents

Switch to ATV-containing regimen
ASSURE
Original article : Wohl D, ICAAC 2012; Abs H556c ; Wohl D, ICAAC 2013; Abs H665
Last update : Epub 2007 Nov 13

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Similar nature and rate of Grade 2-4 clinical adverse events
  • Grade 2-4 adverse event leading to study withdrawal
    • ATV + ABC/3TC, n = 8 (rash = 2, nausea = 3, vomiting = 2) ;
    • ATV/r + TDF/FTC, n = 2
  • Grade 3-4 laboratory abnormalities
    • ATV + ABC/3TC : 19% (hyperbilirubinemia 6%)
    • ATV/r + TDF/FTC : 36% (hyperbilirubinemia 29%) [p < 0.001 vs ATV + ABC/3TC]
  • Significant improvements observed in bone biomarkers (BAP, PTH, CĀ­telopeptide, and osteocalcin), renal urine b2 microglobulin/ creatinine ratio in the ATV + ABC/3TC group

Design :


Primary Endpoints :

  • Non inferiority in the proportion of patients with HIV RNA < 50 c/mL at W24 (TLOVR algorithm), lower limit of the 95% CI for the difference = - 12%

Baseline characteristics and patient disposition :

Outcome at week 24



Outcome at week 48 :

Confirmed virologic failure

  • ATV + ABC/3TC : 2%
  • ATV/r + TDF/FTC : 1%

 

dia dia dia
dia dia dia

Back to Table of Contents

     
     
     
Copyright AEI 2017 | Links | Contact | Faculty and Disclosure | Terms of use aei